Jinzhou Ahon Pharma, a subsidiary of Shanghai Fosun Pharma, in-licensed greater Chinarights to a candidate for an ischemic stroke treatment from DiaMedica Therapeutics of Minneapolis in a $32.5 million agreement. DM199 (synthetic KLK1 protein) can be administered up to 24 hours after the onset of a stroke, longer than the 3 to 4.5 hours of tPA, the current standard of care. Previously, Fosun made an equity investment in DiaMedica. Ahon specializes in cardiovascular and CNS drugs.
Source: China Biotoday
